A series called ‘Gonads’ by RadioLab is looking into human reproduction. Their second episode, which is the source used for this article, can be found here. It explores the story of Greg…
A study that looked into what genetic factors influence medulloblastoma development has been published in Lancet Oncology. In it, researchers outline several genes they believe are linked to tumour formation…
According to a story from pm360online.com, the clinical stage corporation Epizyme recently released detailed results from the Phase 2 trial of its leading investigational candidate, tazemetostat. This drug is in…
The not-for-profit healthcare organisation Sanford Health is planning to implement routine genetic testing for patients to identify a patient’s risk for a range of rare, and more common, diseases. The…
Autoimmune Polyglandular Syndrome Type 1 What is autoimmune polyglandular syndrome type 1 (APS1)? Autoimmune polyglandular syndromes (APSs), also called autoimmune polyendocrine syndromes, are a group of rare diseases that all…
What happens when you’re not the cancer that everyone is talking about? Funding, research, and headlines can often be noticeably lacking when you’re just a run-of-the-mill, life-threatening gene mutation, according…
Acute diagnosis is the Holy Grail for all illnesses and conditions. But what if you could predict the likelihood that you would develop a deadly disease and take steps to…
They say that technology has made life easier, faster, more comfortable, and on and on and on. Who this “they” is, I don’t know. While technology has made certain parts…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
